Alzheimer's is the most common form of dementia. The condition is forecast to affect 153 million people worldwide by 2050, which is why researchers have been testing approaches beyond drugs that target amyloid.
A once-daily pill from the same drug family as Viagra slowed cognitive decline by 31% in people with early Alzheimer's who were not taking other treatments, a late-stage trial suggests, but the benefit did not hold for the study as a whole.
Researchers presented the findings at the Clinical Trials on Alzheimer's Disease conference in Boston. Independent experts called the subgroup result exciting and very promising, while urging caution and further trials before any prescription use.
In a stage three trial spanning 13 countries, including the UK, the tablet AR1001 slowed decline by 31% in patients with early Alzheimer's who were not receiving any other treatment for the disease.
That benefit was not significant across the overall trial group. In a wider group of patients who were taking other drugs, the tablet did not achieve statistically significant results.
MedPage Today and AriBio reported that in the overall population of 1,535 participants, AR1001 did not reach statistical significance on the primary endpoint. The difference on the CDR-SB scale was minus 0.11 points, with a p value of 0.4015.
Researchers said the drug takes a novel approach and, rather than targeting amyloid, acts on a specific enzyme and influences several other processes involved in brain function.
One researcher said the drug acts by boosting blood flow and likely also by directly stimulating pathways in brain cells that promote learning and memory.
Over the year of the trial, the drug slowed decline in memory and thinking by nearly a third among the patients who showed a benefit, a researcher said. Side effects reported were mostly mild to moderate, he said.
He said the drug did not seem to be as effective for people taking other medicines for Alzheimer's symptoms, and that this needed further investigation. The trial showed a statistically significant slowing of clinical decline only in participants who were not taking other commonly used Alzheimer's medications alongside the trial drug.
Unlike other disease-modifying treatments that have shown benefit in late-stage trials, AR1001 is taken as a once-a-day tablet, which could make treatment simpler if it is eventually approved.
Experts not involved in the study said the results could signal a totally new treatment for Alzheimer's. They also said the findings were an encouraging development and reinforced the case for exploring different approaches to a complex disease.
All of the experts called for further trials. They said AR1001 would have to be scrutinised by the scientific community and by drug regulators before it could be prescribed to treat Alzheimer's.